THIS SHARE WILL BE WORTH 3.00 IN 2009

Astrazeneca, are according to the weekend press looking for more tie-ups or licensing deals. They have even created a high level post, with sole responsibility to search for such deals. The main company mentioned in the article was the licensing deal with Protherics. Could they return looking for more. Even if not it was a nice little bit of publicity.

Re RNS
M&G Investment Management Limited , Prudential plc and certain of its subsidiary companies held a notifiable interest in 10,431,716. This is an increase from the 9,873,542 held on 25/01/06. Good to see the institutions increasing their holdings especially the way the stock market is lately.

Yes, it does show confidence in PTI which is especially engouraging bearing in mind the way the sp has stagnated of late.

Queen1,

Stagnation? - take a longer view chum. The chart is as positive a chart than i have seen this side on Christmas. Give it more time and the rewards will come.

It's moved sideways and down since I bought in "chum".

mmm so that was at most a month ago - come on be serious.
3 months view is a gamble - look 3 years ahead and you will make real money.

It was earlier than that but I'm in to make money so sitting tight.

Snakebite-serum firm on growth trail May 31 2006

David Williamson, Western Mail

SNAKEBITE serum manufacturer Protherics is preparing for global growth through a programme to help its managers identify weak links in their chain of command.

http://icwales.icnetwork.co.uk/0300business/0100news/tm_objectid=17150939&method=full&siteid=50082&headline=snakebite-serum-firm-on-growth-trail-name_page.html

Results as expected, and the next 2 to 3 year prospects look very good indeed.

Strong cash position at end of period of 25.4 million (2005: 7.3 million), following CytoFab(TM) upfront payment and equity contribution from AstraZeneca.

If you dig out the cash facts after all the ins and outs of R+D, acquisitions, investments etc, this paragraph reads well, and just about sums up the cash position.

Cash inflow from operating activities was 12.6 million compared to an outflow
of 2.8 million in the prior year. Although the operating loss for the year was
9.5 million, only 0.7 million of the initial 16.3 million non refundable
receipt from AstraZeneca was recognised as income in the period, and this is
reflected in the increased cash inflow from operations.

I think this may make the market sit up and take a bit more notice. There is a good indication in these results of things to come.

Well the market appears to like it, at 5.25p ( 6.35 ) up on a relatively good turnover of 1.93 million shares traded. This leads me to believe that institutional investment is about to increase.

Greekman - Looking good eh.
This one is a winner plenty more in the pipeline too.
Must be worth another 50p or so dont you think?

Hi Transco,

Nice of someone to join me, I was getting a bit lonely out here. Yes I think we will see the share price at nearer 2 within 12 to 18 months as long as there are no big hiccups along the way. I don't usually state any opinion or prediction re future share price as it nearly always comes out as a ramp/deramp but I think the prospects are endless for PTI if we are patient and look many year ahead. As we know drugs can be a very up and down business, as the larger companies often tell us. For it's size PTI must be the best such type of company around, with a very good product line and a management that knows what it's all about.

A nice snippet from Motley Fool.

A Tempting Biotech Bet
By Ed Bowsher (TMFArkle)
June 7, 2006

I think it's a good time to look at one of the UK's better biotech companies -- Protherics (LSE: PTI). I'm not saying that Protherics is an inevitable bid target, but I do think it looks undervalued. The most exciting product in the company's portfolio is a drug for severe sepsis called Cytofab.

http://www.fool.co.uk/news/comment/2006/c060607f.htm?ref=foolwatch

HI greekman/ I THINK THAT IF YOU READ THAT NOTE CORRECTLY ?ITS POINT TO A FOUR YEAR LIFESPAN TO COME RIGHT////

Hi Bristlelad,

Yes, had seen the 4 year bit, but with PTI's list of products at their relevant stages, and with the bigger companies such as AstraZeneca sniffing around that's what make me ( possibly a bit rash ) go for the 2 sp in 12 to 18 months.
My bit " but I think the prospects are endless for PTI if we are patient and look many year ahead " is looking at the 4 year plus note. But who knows.

The Daily Telegraph quote David Brennan Chief Exec of AstraZeneca as stating they will look to further acquisitions to bolster its drugs pipeline. They are mostly interested in areas were they have a substantial presence. I can see a move for PTI. I hope they do stay independent for the reasons already mentioned re the next few years prospects, but if the offer is good enough who knows. Money talks and AZ have plenty of it.

Piper Jaffray to Host First Ever London Health Care Conference
Monday June 19, 1:00 am ET

Companies scheduled to present and attend the London Health Care Conference include: Protherics Plc,
Ok there are many companies presenting, but any such appearances can only do companies such as those with PTI's innovative products good. Will be nice to see what interest the media show after the event.

Hi!

I am a newcomer to this site-very interested to see the postings re Protherics-what do seasoned members think of Alizyme?

Protherics gives CoVaccine's novel adjuvant a shot
By Gregory Roumeliotis.

21/06/2006 - Biopharmaceutical firm Protherics has acquired a new adjuvant from Dutch company CoVaccine that it will use for its hypertension vaccine, hoping to boost antibody production by tenfold.

http://www.in-pharmatechnologist.com/news/ng.asp?n=68578-protherics-angiotensin-covaccine-adjuvant

Very strange, or is it.

Eight what look like test trades go through as buys, totaling 494 shares, then 2 x 1,450,000, out of hour trades mid range go through. Will be interesting to see what they open at tomorrow.